Antibacterial protein EFAL-2 having bacteriolytic ability with respect to Enterococcus faecium
Inventors
Yoon, Seong Jun • Kang, Myung Soo • JUN, Soo Youn • Kim, Jong Hyun • Jung, Gi Mo • Son, Jee Soo • Paik, Hyoun Rok • Kang, Sang Hyeon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11492378-B2
Publication Date
2022-11-08
Expiration Date
Abstract
The present invention relates to an antibacterial protein EFAL-2 derived from bacteriophage Ent-FAP-4 (Accession number: KCTC 12854BP), which has the ability to kill Enterococcus faecium and an amino acid sequence represented by SEQ ID NO: 2, a pharmaceutical composition containing the same as an active ingredient, and a method for preventing or treating diseases caused by Enterococcus faecium using the pharmaceutical composition.
Core Innovation
The document discloses an antibacterial protein named EFAL-2 derived from bacteriophage Ent-FAP-4 (KCTC 12854BP). EFAL-2 is defined by an amino acid sequence represented by SEQ ID NO: 2, and a corresponding gene sequence represented by SEQ ID NO: 1. The protein has bacteriolytic ability against Enterococcus faecium.
The document further discloses recombinant production of EFAL-2 in E. coli TOP10-pBAD-EFAL-2 (KCTC 13177BP). It describes pharmaceutical compositions comprising EFAL-2 for preventing or treating Enterococcus faecium infections, including urinary tract infection, wound infection, bacteremia, and endocarditis, including antibiotic-resistant strains.
The document reports bacteriolytic specificity, with activity only against Enterococcus faecium in spot and turbidity reduction assays. It also discloses an in vitro prevention model showing growth inhibition and killing of Enterococcus faecium, and a mouse infection model reporting improved survival without specific adverse reactions described.
Claims Coverage
The provided independent claim contains 2 inventive features: (1) a treatment method for endocarditis caused by Enterococcus faecium, and (2) administration of a composition containing an antibacterial protein with bacteriolytic ability that is limited to the amino acid sequence represented by SEQ ID NO: 2.
Endocarditis treatment by administering EFAL-2 composition
A method for treating endocarditis caused by Enterococcus faecium by administering to a subject a composition comprising an antibacterial protein having bacteriolytic ability against Enterococcus faecium.
SEQ ID NO: 2 sequence-limited antibacterial protein
The administered composition comprises an antibacterial protein consisting of the amino acid sequence represented by SEQ ID NO: 2.
Across the provided independent claim, the invention centers on administering a composition for treating endocarditis caused by Enterococcus faecium, where the antibacterial protein is defined specifically as the bacteriolytic protein EFAL-2 consisting of the amino acid sequence of SEQ ID NO: 2.
Stated Advantages
High specificity for Enterococcus faecium with minimal/no activity against other tested bacteria.
Bacteriolytic activity only against Enterococcus faecium in spot and turbidity reduction assays.
Growth inhibition and killing in an in vitro prevention model.
Improved survival in a mouse infection model (0% mortality vs 60% in control).
No specific adverse reactions reported.
Documented Applications
Preventing or treating Enterococcus faecium infections, including urinary tract infection, wound infection, bacteremia, and endocarditis.
Treatment of endocarditis caused by Enterococcus faecium by administering a composition comprising the antibacterial protein EFAL-2 (SEQ ID NO: 2).
Use in infections including antibiotic-resistant strains.
Interested in licensing this patent?